Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks .

What is Agios Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $41.00. On average, they expect the company's share price to reach $35.20 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts .

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of 2023. Since then, AGIO shares have decreased by 21.5% and is now trading at $22.05. View the best growth stocks for 2023 here .

Are investors shorting Agios Pharmaceuticals?

Agios Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,020,000 shares, an increase of 6.4% from the October 31st total of 5,660,000 shares. Based on an average daily volume of 531,600 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.0% of the shares of the company are short sold. View Agios Pharmaceuticals' Short Interest .

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our AGIO earnings forecast .

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $0.05. The biopharmaceutical company earned $7.40 million during the quarter, compared to the consensus estimate of $7.73 million. Agios Pharmaceuticals had a negative net margin of 913.95% and a negative trailing twelve-month return on equity of 22.03%.

What ETFs hold Agios Pharmaceuticals' stock?

ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT) , Virtus LifeSci Biotech Products ETF (BBP) , WisdomTree BioRevolution Fund (WDNA) and ALPS Medical Breakthroughs ETF (SBIO) . Simplify Propel Opportunities ETF (SURI) .

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com . Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD) , Micron Technology (MU) , Alibaba Group (BABA) , bluebird bio (BLUE) , Pfizer (PFE) , Vertex Pharmaceuticals (VRTX) , NVIDIA (NVDA) , Tesla (TSLA) and Netflix (NFLX) .

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (9.30%), Armistice Capital LLC (5.95%), Rock Springs Capital Management LP (4.85%), JPMorgan Chase & Co. (4.42%), Northern Trust Corp (1.10%) and Deutsche Bank AG (1.04%). Insiders that own company stock include Brian Goff, Carman Alenson , Cecilia Jones, Christopher Bowden , Darrin Miles , David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn. View institutional ownership trends .

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Agios Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AGIO)

$22.05

-1.09 (-4.71%)

(As of 12/8/2023 ET)

Compare

Today's Range: $22.01
▼
$23.14
50-Day Range: $19.97
▼
$24.53
52-Week Range: $19.80
▼
$31.87

Volume: 392,101 shs
Average Volume: 391,638 shs
Market Capitalization: $1.23 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.20

Agios Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 59.6% Upside
$35.20 Price Target
Short Interest: Bearish
10.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.60
Upright™ Environmental Score
News Sentiment: 0.61
Based on 5 Articles This Week
Insider Trading: Selling Shares
$54,017 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($6.25) to ($4.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

657th out of 942 stocks

Pharmaceutical Preparations Industry

315th out of 448 stocks

3.3

Analyst's Opinion

Consensus Rating
Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.20, Agios Pharmaceuticals has a forecasted upside of 59.6% from its current price of $22.05.
Amount of Analyst Coverage
Agios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
10.99% of the float of Agios Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Agios Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Agios Pharmaceuticals has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Agios Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Agios Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Agios Pharmaceuticals has received a 73.83% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Agios Pharmaceuticals is -0.60.

2.6

News and Social Media Coverage

News Sentiment
Agios Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.
MarketBeat Follows
2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,017.00 in company stock.
Percentage Held by Insiders
Only 4.24% of the stock of Agios Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.25) to ($4.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Agios Pharmaceuticals is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Agios Pharmaceuticals is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Agios Pharmaceuticals has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AGIO Stock News Headlines

December 9, 2023 | americanbankingnews.com

Q3 2024 Earnings Estimate for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Issued By Zacks Research

December 6, 2023 | finance.yahoo.com

Agios Pharmaceuticals (NASDAQ:AGIO) shareholders have endured a 59% loss from investing in the stock five years ago

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 22, 2023 | thestreet.com

Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'

November 20, 2023 | finance.yahoo.com

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

November 6, 2023 | markets.businessinsider.com

Agios Pharma Stock Receives ‘Buy’ Rating: Promising Financial Results, Pipeline Updates, and Upcoming Catalysts Justify Optimism

November 5, 2023 | benzinga.com

Agios Pharmaceuticals Stock (NASDAQ:AGIO), Analyst Ratings, Price Targets, Predictions

November 5, 2023 | finance.yahoo.com

Calculating The Fair Value Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

December 9, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 3, 2023 | markets.businessinsider.com

Agios Pharma’s Promising Outlook: Expanding Pyruvate Kinase Activator Portfolio, Clinical Progress and Solid Financial Stability Prompt Buy Rating

November 3, 2023 | finance.yahoo.com

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript

November 2, 2023 | seekingalpha.com

Agios Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 2, 2023 | msn.com

Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13M

November 2, 2023 | finance.yahoo.com

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

November 2, 2023 | finance.yahoo.com

Agios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net Revenue

November 1, 2023 | msn.com

Agios Pharmaceuticals Q3 2023 Earnings Preview

October 19, 2023 | finance.yahoo.com

Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023

September 14, 2023 | markets.businessinsider.com

Nektar Therapeutics (NKTR) Gets a Sell from Bank of America Securities

September 9, 2023 | finanznachrichten.de

Regeneron Pharmaceuticals, Inc.: Regeneron Announces Updates to Board of Directors

September 7, 2023 | finance.yahoo.com

Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?

September 3, 2023 | markets.businessinsider.com

J.P. Morgan Reaffirms Their Hold Rating on Sana Biotechnology (SANA)

August 30, 2023 | uk.finance.yahoo.com

Agios Pharmaceuticals Inc (8AP.BE)

August 29, 2023 | finance.yahoo.com

Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023

August 22, 2023 | benzinga.com

Agios Pharmaceuticals Insider Trades Send a Signal

August 10, 2023 | benzinga.com

Principal Accounting Officer At This Health Care Company Sells $74K of Stock

August 10, 2023 | finance.yahoo.com

The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake

August 8, 2023 | msn.com

JP Morgan Maintains Agios Pharmaceuticals (AGIO) Neutral Recommendation

See More Headlines

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AGIO
CUSIP: N/A
CIK: 1439222
Web: www.agios.com
Phone: (617) 649-8600
Fax: N/A
Employees: 389
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.20
High Stock Price Target: $41.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +59.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-231,800,000.00
Net Margins: -913.95%
Pretax Margin: -913.95%
Return on Equity: -22.03%
Return on Assets: -19.60%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.06
Quick Ratio: 11.76

Sales & Book Value

Annual Sales: $14.24 million
Price / Sales: 86.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $20.03 per share
Price / Book: 1.10

Miscellaneous

Outstanding Shares: 55,890,000
Free Float: 53,521,000
Market Cap: $1.23 billion
Optionable: Optionable
Beta: 0.93

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Brian M. Goff M.B.A. (Age 54)
CEO & Director
Comp: $1.23M
Ms. Cecilia Jones (Age 48)
Chief Financial Officer
Comp: $403.36k
Mr. James William Burns (Age 45)
Corporate Secretary & Chief Legal Officer
Comp: $660.33k
Dr. Sarah Gheuens M.D. (Age 43)
Ph.D., Chief Medical Officer and Head of Research & Development
Comp: $769.2k
Dr. Lewis Clayton Cantley Ph.D. (Age 74)
Co-Founder & Member of Scientific Advisory Board
Comp: $50k
Dr. Tak Wah Mak D.Sc. (Age 77)
FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
Dr. Craig B. Thompson M.D. (Age 70)
Co-Founder & Chairman of Scientific Advisory Board
Dr. Shin-San Su Ph.D. (Age 67)
Co-Founder & Member of Scientific Advisory Board
Mr. T. J. Washburn Jr. (Age 42)
Principal Accounting Officer
Dr. Clive Patience Ph.D. (Age 59)
Chief Technical Operations Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AGIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.
What is Agios Pharmaceuticals' stock price target for 2024?: 4 Wall Street research analysts have issued 1 year price objectives for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $41.00. On average, they expect the company's share price to reach $35.20 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.
How have AGIO shares performed in 2023?: Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of 2023. Since then, AGIO shares have decreased by 21.5% and is now trading at $22.05.
View the best growth stocks for 2023 here.
Are investors shorting Agios Pharmaceuticals?: Agios Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,020,000 shares, an increase of 6.4% from the October 31st total of 5,660,000 shares. Based on an average daily volume of 531,600 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.0% of the shares of the company are short sold.
View Agios Pharmaceuticals' Short Interest.
When is Agios Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our AGIO earnings forecast.
How were Agios Pharmaceuticals' earnings last quarter?: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $0.05. The biopharmaceutical company earned $7.40 million during the quarter, compared to the consensus estimate of $7.73 million. Agios Pharmaceuticals had a negative net margin of 913.95% and a negative trailing twelve-month return on equity of 22.03%.

What ETFs hold Agios Pharmaceuticals' stock?: ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Propel Opportunities ETF (SURI).
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?: 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Agios Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).
Who are Agios Pharmaceuticals' major shareholders?: Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (9.30%), Armistice Capital LLC (5.95%), Rock Springs Capital Management LP (4.85%), JPMorgan Chase & Co. (4.42%), Northern Trust Corp (1.10%) and Deutsche Bank AG (1.04%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends.
How do I buy shares of Agios Pharmaceuticals?: Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AGIO) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial